Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | HRH2 | P25021 | 2/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599648 | 0.97 | HRH3 (0.55) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL13636153 | 0.88 | SIGMAR1 (0.65) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL10123161 | 0.86 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19KDM4E | |
| SCHEMBL2847777 | 0.85 | HRH3 (0.69) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL22765331 | 0.83 | TMEM97 (0.57) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL3678408 | 0.83 | TMEM97 (0.57) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL12524374 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19KDM4E | |
| SCHEMBL2848828 | 0.82 | HRH3 (0.65) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL5103812 | 0.82 | CHRM1 (0.61) | TMEM97SIGMAR1HRH3HTR1AHRH2 | |
| SCHEMBL17150542 | 0.81 | SMN1; SMN2 (0.56) | TMEM97SIGMAR1HRH3HTR1AHRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| EP-2391617-B1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912176-B2 | Azetidines as histamine H3 receptor antagonists | EVOTEC AG (DE) | 2014-12-16 | — | — | US | disclosed |
| CN-102369196-A | Azetidines as histamine h3 receptor antagonists | EVOTEC NEUROSCIENCES GMBH | 2012-03-07 | — | — | CN | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2012-02-16 | — | — | US | disclosed |
| EP-2391617-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-12-07 | — | — | EP | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
| WO-2010086403-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040952-A1 | AZETIDINES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH3, HRH2, HRH1 | TMEM97 208/4885SIGMAR1 58/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.